

# Index

*Compiled by Caroline Sheard*

Page numbers in *italic* refer to tables and/or text in boxes

- Abbreviated Mental Test Score (AMTS)  
4–5, 10–11, 31  
in Alzheimer's disease 57  
in delirium 41
- ABC analysis of behaviour 94
- abnormal beliefs 8
- abstract thinking impairment in delirium 31
- N-acetylaspartate 186–187
- N-acetylcarnitine 249
- acetylcholine in Alzheimer's disease 68, 249
- acetylcholinesterase inhibitors 249, 322
- activities of daily living, history taking 6
- affective disorders  
in Alzheimer's disease 52–53  
imaging 108, 188–189  
spectrum 125  
*see also* depression
- after-care 307–309
- age  
and onset of delirium 34  
of residents in residential care 232
- Age Concern 205
- AGECAT 13–14, 23
- ageing  
and behaviour 164–165  
effect on alcohol metabolism 169  
histological changes in 65
- aggression in dementia 91
- agnosia in Alzheimer's disease 52
- agoraphobia 139
- AIDS, dementia in 83
- alcohol  
acute intoxication 172  
consumption trends 170  
dependence 168–176  
aetiology 170  
early-/late-onset 170  
epidemiology 169–170  
in general hospital 212  
management 175–176  
medical complications 170–174  
patient management problem 334–335  
presentation 174–175  
rehabilitation 176
- detoxification 175
- drug interactions 172
- effect of ageing on metabolism 169
- social drinking 174
- use  
and delirium 35  
and dementia 84  
history taking 5–6  
withdrawal regime 175  
withdrawal syndrome 172
- alcoholic cerebellar degeneration 173
- alms houses 226
- aluminium and Alzheimer's disease 63
- Alzheimer's disease 49–72  
aetiology 61–64  
assessment 57–59  
brain atrophy in 182, 183  
cerebral glucose metabolic rate 186  
clinical features 51–54  
coupling in 185–186  
diagnostic criteria 54, 56–57, 66  
differential diagnosis 54  
drug therapy 249, 322  
early onset 54  
epidemiology 50–51  
genetics 61–62  
hippocampal atrophy in 183  
history-taking 57  
imaging 58, 182, 183, 184, 185, 186, 187  
late onset 54  
neurochemistry 68–69  
neuropathology 64–8  
patient management problem 329–330

- prevalence 51
- prognosis 60–61
- regional cerebral blood flow 184
- subtypes 53–54
- white matter lesions 183
- see also* dementia
- Alzheimer's Disease Society 205
- amines in depression 110
- amitriptyline 252, 253
- amnesia in Alzheimer's disease 51
- AMTS *see* Abbreviated Mental Test Score
- amygdala, volume measurement 183
- amyloid in Alzheimer's disease 61, 67
- amyloidosis with hereditary cerebral haemorrhage 78–79
- amyotrophic lateral sclerosis 65
- analytic studies 314
- anhedonia 104
- anticholinergic drugs as precipitators of delirium 37
- anticholinesterases 249
- anticipatory grief 276
- anticonvulsants 254
- antidepressants
  - atypical 252
  - choice of 252–255, 256
  - classification 252
  - in comorbidity 254–255
  - compliance 254
  - continuation therapy 255
  - contraindications 253
  - cost 254
  - in dementia 89, 251
  - in depression 113–14, 114–15
  - drug interactions 254
  - efficacy 252
  - interactions with alcohol 172
  - prophylactic 119, 255–256
  - in residential care 242
  - safety 252
  - side-effects 253–254
  - tricyclic 252, 256
- antihistamines 144
- antipsychotics *see* neuroleptics
- anxiety 7
  - in general hospital 211–212
  - generalised 136, 140
  - management 271
  - patient management problem 333–334
  - see also* neurotic disorders
- anxiolytics, drug interactions 254
- aphasia 11, 51
- apolipoprotein E 62, 183
- appearance 7
- apraxia 11, 52
- arrest 298
- arterial dissection 77
- aspirin in vascular dementia 249–250
- assessment 1–15
  - legal aspects 291
  - location 2–3
  - patient management problem 327–328
  - in residential care 237, 241
- astrocytes, in Alzheimer's disease 67
- attachment and depression 112
- attempted suicide 22
- bank accounts 299
- barbiturate interactions with alcohol 172
- BASDEC 12, 13
- BDRS 14
- BEHAVE-AD 53
- behaviour
  - and ageing 164–165
  - assessment 7
  - and carer stress 281
  - characteristics of residents in residential care 232–233
  - disorders
    - in dementia 53, 90–93
    - in depression 105
- behavioural analysis in dementia 93–94
- benzodiazepines 5
  - in aetiology of delirium 35
  - in dementia 251
  - dependence on 176–177
  - interactions with alcohol 172
  - in neurotic disorders 143–144
  - in sleep disorders 260–261
  - in therapy of delirium 44
  - withdrawal regime 176
- bereavement 109, 272
  - counselling 116, 271–272
  - living 276

- best interests 293  
 beta-blockers  
   in dementia 251  
   drug interactions 254  
 Binswanger's disease 74–75  
 birth cohort studies 20  
 bleeding and delirium 36  
 Blessed Dementia Rating Score 14  
 body image disturbance in delirium 30  
 bovine spongiform encephalopathy 82  
 brain  
   atrophy 58  
     in alcohol dependence 173–174  
     in Alzheimer's disease 64  
     imaging 180, 182  
   changes in depression 111  
   damage  
     and delirium 34  
     and dementia 55  
   disease  
     and late paraphrenia 154–155  
     and mania 128–129  
     ventricular enlargement 58  
     white matter lesions 183–184, 188  
 Brief Assessment Schedule Depression Cards 12, 13  
 BSE 82  
 building society accounts 299  
 buspirone 144, 251  
 butyrophenones 257  
 Buxton chair 214
- CADASIL 75, 77–78  
 Caerphilly Study 20  
 CAGE questionnaire 6, 174, 212  
 calcium 107–108  
 Cambridge Examination for Mental Disorders of the Elderly (CAMCOG/CAMDEX) 10, 11, 12, 14, 23, 57  
 Canberra Interview 22, 23  
 cancer and alcohol dependence 171  
 capacity 292  
 CAPE 10, 12, 13, 14  
 Capgras syndrome 52  
 carbamazepine  
   in dementia 251  
   drug interactions 259  
   in mania 130, 131  
 CARE 14
- Care Programme Approach 98–99, 199, 205, 307–308  
 carers  
   counselling 285  
   interviewing 3  
   male 281–282  
   and outcome of depression 113  
   patient management problem 339–340  
   stress 275–276  
     causes 281–283  
     effects 283  
     extent of 279–280  
     factors associated 283  
     measures 279  
     reduction 283–285  
     support 96–97, 285, 323  
 case-control studies 21, 314  
 case registers 19–20  
 cellulitis and delirium 36  
 census information 19  
 cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy 75, 77–78  
 cerebral embolism and delirium 36  
 cerebral haemorrhage 78–79  
 cerebral vasculitis 78  
 child sexual abuse 112  
 chloral hydrate 172, 261  
 chlordiazepoxide 175, 260  
 chlormethiazole 175, 260, 261  
 chlorpromazine 257  
   in dementia 250  
   side-effects 259  
 cholinergic system 248  
 chronic subdural haematoma 79  
 cimetidine 259  
 civil rights 292  
 Clifton Assessment Procedure for the Elderly 10, 12, 13, 14  
 clock drawing test 10, 12  
 clomipramine 252  
 clozapine 257, 258  
   in dementia 250–251  
   side-effects 259  
   in treatment-resistant schizophrenia 259  
 CMHNS 199, 200–201, 205, 240  
 co-dergocrine mesylate 249  
 cognitive assessment 8

- in Alzheimer's disease 57
  - rating scales 10–12
- cognitive-behavioural therapy 270–271
  - in depression 115–116
  - in neurotic disorders 143
- cognitive impairment
  - in Alzheimer's disease 60–61
  - in depression 117–118
- cohort studies 314
- Columbia University Scale for Psychopathology in Alzheimer's Disease 53
- communication and carer stress 281
- community care 197–198, 205
- Community Care Act 1990 98
- community hospitals 236
- community mental health nurses 199, 200–201, 205, 240
- comorbidity, iatrogenic 212
- comprehension impairment in delirium 31
- Comprehensive Assessment and Referral Evaluation 14
- compulsory admission 303–309
- computerised tomography (CT) 180
  - affective disorders 188
  - dementia 58, 182
  - late paraphrenia 155, 189
  - neurotic disorders 138
- concentration, assessment 11
- confidentiality 292, 315
- confounding variables 21
- confrontation 267
- Confusion Assessment Method Questionnaire 41
- Confusional State Evaluation 41–42
- consciousness impairment in delirium 30
- consent to treatment 309–311, 315
- contracts 297–298
- corticotrophin releasing factor in Alzheimer's disease 69
- coupling 185–186
- Court of Protection 301–303
- CPA 98–99, 199, 205, 307–308
- Creutzfeldt–Jakob disease 59, 82, 182, 184
- Crichton Royal Behavioural Rating Scale 232, 233
- cross-sectional studies 20
  - CSE 41–42
  - CT *see* computerised tomography
  - CUSPAD 53
  - cyclothymia 125
- day care 202–203, 284
- day hospital, assessment in 2
- death in residential care 239–240
- delirium 27–48
  - aetiology 33–37
  - classification 28, 29
  - clinical features 30–32, 33
  - definitions 28
  - and dementia 34, 210
  - diagnosis 29, 41–42
  - differential diagnosis 37–41
  - drug therapy 252
  - epidemiology 20
  - in general hospital 209, 210
  - historical context 27–28
  - history taking 41
  - hyperalert-hyperactive 32
  - hypoalert-hypoactive 32
  - investigations 42
  - in literature 27–28
  - management 42–44
  - mechanisms 37
  - mixed 32
  - natural history 32–33
  - patient management problem 329
  - physical examination 42
  - precipitating factors 35–37, 38
  - predisposing factors 34–35
  - prognosis 44–45
  - rating instruments 41–42
- Delirium Rating Scale 41
- Delirium Symptom Interview 41
- delirium tremors 172
- delusional disorder 152
- delusions
  - in Alzheimer's disease 52
  - in dementia 89–90
  - in late paraphrenia 149–150
  - and making a will 296
- dementia
  - alcoholic 173–174
  - Care Programme Approach 98–99
  - and carer stress 280
  - concurrent illness 88–90
  - and delirium 34, 210

- and depression 89, 90, 117–118, 254–255
- differential diagnosis 37–40, 54, 55
- drug-induced 84
- drug therapy 93, 249–251, 322
- epidemiology 49–50
- features 39
- frontal lobe type 55
- frontotemporal 80, 81, 185
- and gender 50
- in general hospital 209, 210
- historical context 87
- imaging 58, 182–187
- incidence 50
- infective 83
- with Lewy bodies 55, 79–80
  - drug therapy 250
  - histological changes in 65
  - imaging 185
- management 87–101, 331–332
- metabolic and endocrine 83
- multi-infarct 74, 79
- neoplastic 84
- and neurotic disorders 138
- and personality disorder 166–167
- prevalence 49–50
- primary health care 97–98
- prion 82
- psychological therapies 93–94, 272–275
- and residential care 234
- social interventions 94–96
- support for carers 96–97
- toxin-related 55
- treatable 83–85, 88
- troublesome behaviours in 90–93
- see also Alzheimer's disease; vascular dementia
- dementia pugilistica 55, 62–63, 65
- demographic trends 16–18, 225
- dependency 266–267
- depression 102–124
  - aetiology 110–13
  - in Alzheimer's disease 52–53
  - assessment 12–13, 106–109
  - biological markers 108–109
  - bipolar 125
  - classification 102, 103
  - clinical features 102–106
  - coexistence with physical illness 104, 107, 111, 210–211, 320
  - complaints of 104
  - and dementia 89, 90, 117–118, 254–255
  - differential diagnosis 40, 109
  - drug therapy 252–256
    - see also antidepressants
  - early-/late-onset 111
  - epidemiology 102
  - factors altering or obscuring presentation 104
  - in general hospital 209, 210–211
  - history-taking 106–107
  - imaging 108, 188–189
  - management 113–116
  - 'neurotic' 141
  - patient management problem 332
  - perpetuating factors 113
  - and personality disorder 165
  - precipitating factors 112–113
  - predisposing factors 110–112
  - prognosis 116–120
  - prophylaxis 119–120, 255–256
  - relapse 119
  - and residential care 234
  - treatment-resistant 114–115, 255
  - unipolar 125
- Depressive Signs Scale 12, 13, 89, 90
- descriptive studies 314
- desferrioxamine 249
- dexamethasone suppression test 108–109
- diabetes and delirium 36
- diagnosis 9
- Diagnostic and Statistical Manual of Mental Disorders* (DSM-IV) 9, 22
- neuroses 134
- personality disorders 163
- diagnostic criteria and research 319
- Diagnostic Interview Schedule 22
- diazepam 44
- dibenzapines 257
- Diogenes' syndrome 166
- dissociative disorders 142–143
- district nursing in residential care 239
- district psychogeriatric service 196–197
- divorce 295–296
- domiciliary care agencies 205
- domiciliary visits 2

- Domus philosophy of residential care 96
- donepezil 248, 249, 261, 322
- dopamine in Alzheimer's disease 68
- dopaminergic system 248
- dothiepin 119, 252
  - prophylactic 256
  - side-effects 253
- Down's syndrome, histological changes
  - in 65
- doxepin 252
- driving 294–295
- DRS 41
- drug dependence 176–177
- drug interactions
  - and alcohol 172
  - antidepressants 254
  - neuroleptics 254, 259
- drug reactions
  - delirium 37
  - dementia 84
- drug therapy 247–264
  - delirium 252
  - dementia 93, 249–251, 322
  - depression 252–256
    - see also* antidepressants
  - history taking 5
  - mania 256–257
  - patient management problem 338
  - schizophrenia 257–260
  - sleep disturbance 260–261
- drugs
  - absorption 247
  - and delirium 35
  - distribution 247
  - excretion 247
  - metabolism 247
  - research studies 321–322
- DSM-IV *see Diagnostic and Statistical Manual of Mental Disorders*
- DST 108–109
- duty of care 310
- dysthymia 125, 316
  
- ECA study 129, 136
- ECG in Alzheimer's disease 58
- echocardiography in vascular dementia 76
- ecological studies 21
- economics and demography 17
- ECT 114, 115
  
- EEG
  - in Alzheimer's disease 59
  - in delirium 42
  - in depression 108, 110–111
- elder abuse 286
- electroconvulsive therapy 114, 115
- embolism, paradoxical 77
- emotional disturbance in delirium 32
- endocrine disorders
  - and delirium 36
  - and dementia 55
- Enduring Power of Attorney 297, 300–301
- environmental disturbance and delirium 34
- environmental restructuring in management of dementia 94–96
- Epidemiologic Catchment Area study 129, 136
- epidemiology 16–26
  - alcohol dependence 169–170
  - Alzheimer's disease 50–51
  - case definition 22
  - definition 18
  - delirium 20
  - dementia 49–50
  - depression 102
  - information sources 19–20
  - interviewers 23–24
  - interviews 23
  - late paraphrenia 152
  - mania 126–127
  - neurotic disorders 135–136
  - patient management problem 328–329
  - psychiatric illness in general hospital 209
  - quality control 24
  - repeatability 24
  - response rates 24
  - sampling 22
  - screening/diagnostic studies 23
  - sources of error 21
  - study stages 21–24
  - study types 20–21
  - terminology 18
  - validity 24
  - vascular dementia 75
- ethics in research 314–316, 317–318
- EURODEM project 50

- experimental studies 314  
 extension of leave of absence 308  
  
 falls and delirium 36  
 family history 4  
 family therapy 116, 268–270, 282, 285  
 fatal familial insomnia 82  
 fear of falling syndrome 211  
 financial affairs 299–303  
 finger agnosia 52  
 fluoxetine 252, 253  
 flupenthixol 257  
 fluvoxamine 253, 254  
 focal cerebral atrophy 55  
 folate deficiency 84, 107  
 fourth age 17  
  
 gamma-aminobutyric acid in  
     Alzheimer's disease 68–69  
 GDS 12–13, 319  
 gender  
     and dementia 50  
     and depression 110  
     and late paraphrenia 153  
     of residents in residential care 232  
 general hospital, psychiatric illness in  
     210–213  
     attitudes to 213–216  
     epidemiology 209  
     screening 213, 214  
 General Household Survey 19  
 general practice, statistics from 19  
 general practitioners, role in residential  
     care 238–239  
 Geriatric Depression Scale 12–13, 319  
 Geriatric Mental State Examination  
     13–14, 23  
 geriatric physician, relationship with old  
     age psychiatrist 219–221  
 geriatric services 204  
 Gerstmann syndrome 52  
 Gerstmann–Straussler syndrome 82  
 gifts 297  
 GMS 13–14, 23  
 gnosis 11  
 granulovacuolar degeneration in  
     Alzheimer's disease 67  
 grief counselling 116, 271–272  
 group therapy 268  
 guardianship 305–307  
  
*Guidelines for Collaboration between  
 Geriatric Physicians and Psychiatrists  
 in the Care of the Elderly* 219  
  
 Hachinski Ischaemia Score 14, 75, 76  
 hallucinations 8  
     alcoholic 173  
     in Alzheimer's disease 52  
     auditory 154  
     in delirium 30  
     in dementia 89–90  
     in late paraphrenia 149–150  
 haloperidol 257  
     in delirium 44  
     in dementia 250  
     drug interactions 254  
     in mania 256  
     in rapid sedation 261–262  
     side-effects 259  
 Hamilton Rating Scale for depression  
     12, 13  
 harmful drinking 168  
     *see also* alcohol dependence  
 Hawthorne effect 315  
 head injury and Alzheimer's disease  
     62–63  
 health services and demography 17  
 hearing loss and late paraphrenia  
     153–154  
 heart disease  
     and alcohol dependence 171  
     and delirium 36  
 hepatic failure and dementia 55  
 hippocampal atrophy 183, 188  
 Hirano bodies 67  
 history 3–7  
 home, assessment in 2, 195–196,  
     200–201  
 home care support services 284–285  
 hospital, assessment in 2–3  
 Hughes Hall Project for Later Life 280  
 Huntington's disease 55, 81  
 hydrocephalus, normal pressure 55,  
     84–85  
 hydroxyproline 64–65  
 hydroxyzine 144  
 hyperparathyroidism and delirium 36  
 hyperthyroidism  
     and delirium 36  
     and depression 108

- hypnotics, drug interactions 254  
hypochondriasis 104, 105, 142, 166  
hypotension, postural 253  
hypothyroidism  
    and delirium 36  
    and depression 108  
hysteria 105
- ICD-10 *see International Classification of Diseases and Related Health Problems*
- illusions in delirium 30
- imaging 180-192  
    affective disorders 108, 188-189  
    dementia 58-59, 182-187  
    depression 108  
    functional 181  
    late paraphrenia 155, 189  
    patient management problem 335-336  
    structural 180
- imipramine 252, 253
- immune system, effects of alcohol  
    dependence on 171
- incapable person  
    consent to treatment 310-311  
    financial affairs 300-303
- incidence, definition 18
- incoherence in delirium 31
- incontinence in dementia 92
- indomethacin 249
- infection and delirium 36
- Informant Questionnaire on Cognitive Decline in the Elderly 42
- information bias 21
- informed consent 309-311, 315
- in-patient care 203-204
- insight, assessment 8
- International Classification of Diseases and Related Health Problems* (ICD-10)  
    9, 22  
    Alzheimer's disease 54, 56  
    delirium 28, 29  
    delusional disorder 152  
    dependence 168-169  
    depression 102, 103  
    differential diagnosis of depression 109  
    mood disorders and mania 126  
    neuroses 134, 135  
    personality disorder 164  
    schizophrenia 151  
    vascular dementia 74
- interviews, epidemiology studies 23
- intimacy and depression 112
- investigations 9  
    in Alzheimer's disease 58  
    in delirium 42  
    in depression 107-108  
    in vascular dementia 76-77
- IQCDE 42
- isoprenaline 248
- jealousy, morbid 173
- joint departments 219
- joint geriatric/psychogeriatric wards 217-218, 219
- joint psychogeriatric assessment units 194-195
- jury service 294
- King Lear* 27-28
- Korsakoff's psychosis 84, 173
- Kuru 82
- language assessment 11
- late paraphrenia *see* paraphrenia
- law 291-312  
    general principles 291-293  
    legal rights of the mentally ill 294-299  
    patient management problem 340  
    reform 293
- leave of absence, extension 308
- leukoariosis 67-68, 75
- Lewy bodies 67, 79-80
- liaison practice 216-221, 337
- life events  
    and depression 112-113, 321  
    and neurotic disorders 138
- life expectancy 17
- life review 267-268
- lithium  
    augmentation therapy in depression 115, 255  
    in dementia 251  
    drug interactions 254, 259  
    in mania 130, 131, 256  
    prophylactic 119-120, 256, 256-257
- litigation 298-299
- liver disease and alcohol dependence 171
- lofepramine 252, 253

- longitudinal studies 20
- lupus anticoagulant syndrome 77
- lymphoma
  - and Alzheimer's disease 63–64
  - and dementia 55
- MADRS 12, 13
- magnetic resonance imaging (MRI) 180
  - advantages and disadvantages 180
  - in affective disorders 108, 188
  - in dementia 58, 183–184
  - in late paraphrenia 155, 189
  - relaxation time 183
- magnetic resonance spectroscopy 181, 186–187
- malingerer 142
- Manchester and Oxford University Scale Psychopathological Assessment of Dementia 53
- mania 125–133
  - aetiology 127–129
  - age of onset 129
  - classification 125–126
  - clinical course 129–130
  - clinical presentation 130
  - differential diagnosis 40
  - drug therapy 256–257
  - dysphoric 126
  - epidemiology 126–127
  - historical context 125
  - management 130–131
  - patient management problem 332–333
  - prognosis 131
  - prophylaxis 256–257
  - secondary 128, 129
- manic–depressive illness 125
- MAOIs 252
- marital status of people in residential care 232
- marital therapy 116, 270
- marriage 295
  - and late paraphrenia 156
- medical history 5
- memory
  - assessment 11
  - impairment
    - age-associated 184–185
    - in delirium 31
- memory clinics 323–324
- memory therapy 274–275
- mental health, residents in nursing/residential homes 234–235
- Mental Health Act 1959 301
- Mental Health Act 1983 93, 114, 291, 304–307, 309–310
- mental health care, in residential homes 240–242
- Mental Health (Patients in the Community) Act 1995 308
- mental illness and legal rights 294–299
- mental incapacity, law reforms 293
- mental state examination 7–8
  - in Alzheimer's disease 57
  - in delirium 41
  - in depression 107
- methylphenidate 251
- metritonate 248
- mianserin 252, 253
- Mini-Mental State Examination (MMSE) 5, 8, 10, 11, 31
  - in Alzheimer's disease 57
  - in delirium 41
  - in depression 107
- mixed affective states 126
- MMSE *see* Mini-Mental State Examination
- moclobemide 252, 253, 254
- monoamine oxidase inhibitors 252
- Montgomery–Åsberg Depression Rating Scale 12, 13
- mood assessment 7
- morbid jealousy 173
- morbidity statistics 19
- mortality
  - and depression 117
  - statistics 19
- motor insurance 295
- motor neurone disease 55
- MOUSEPAD 53
- MRI *see* magnetic resonance imaging
- MRS 181, 186–1877
- multi-disciplinary team 98, 201–202
- narcotics
  - abuse 176
  - pharmacodynamics 248
- National Assistance Act 1948 303–304
- National Health Service and Community Care Act 1994 230

- National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association, diagnostic criteria 56–57
- neurofibrillary tangles 64–65
- neuroleptics
- choice of 258–259
  - classification 257–258
  - contraindications 258
  - in dementia 250–251
  - depot 259–260
  - drug interactions 254, 259
  - effectiveness 258
  - in late paraphrenia 158
  - in mania 256
  - in neurotic disorders 144
  - in residential care 242
  - side-effects 258–259
- Neuropsychiatry Inventory 53
- neurosyphilis 83
- neurotic disorders 105, 134–147
- aetiology 136–138, 139
  - classification 134–135
  - epidemiology 135–136
  - management 143–144
- neurotransmitters in Alzheimer's disease 68–69
- nicotinic acid deficiency 84
- NINCDS–ADRDA, diagnostic criteria 56–57
- nocturnal restlessness in dementia 91–92
- noradrenaline 248
- nortriptyline 252
- NPI 53
- nursing home unit 204
- nursing homes
- accreditation 236
  - characteristics 235–242
  - and demography 225
  - distribution 235
  - historical context 226–231
  - life style and quality within 237–238
  - ownership 235
  - patient management problem 337–338
  - physical health care within 238–240
  - resident characteristics 232–235
  - size 235–236
  - staffing 236–237
  - nutrition and alcohol dependence 171
- obsessive–compulsive disorder 105, 136, 141
- obstructive sleep apnoea and delirium 36
- occupational therapy 239
- OCD 105, 136, 141
- odds ratios 21
- olanzapine 257, 258
- in delirium 44
  - in dementia 251
  - side-effects 259
- old age psychiatry, features 1
- organic solvent exposure and Alzheimer's disease 63
- orientation, assessment 11
- orphenadrine 44
- outcome measures 322–323
- out-patient departments 2
- oxazepam 144
- panic disorder 136, 140
- paranoia 8, 148, 149, 213
- in dementia 89–90
  - see also* paraphrenia
- paranoid ideation in Alzheimer's disease 52
- paraphrenia 40, 148–162
- classification 151–152
  - epidemiology 152
  - historical context 148–149
  - imaging 155, 189
  - management 157–158
  - outcome 158
  - and paranoid personality type 165
  - patient management problem 334
  - risk factors 152–156
  - signs and symptoms 149–151
  - subtypes 156–157
- parkinsonism, drug-induced 258, 260
- Parkinson's disease 55
- dementia in 79–80
  - hippocampal atrophy in 183
  - histological changes in 65
- paroxetine 252
- drug interactions 254
  - side-effects 253
- patient management problems 327–341

- perception
  - in Alzheimer's disease 52
  - in delirium 30–31
- Percy Commission 305
- perphenazine 259
- personal history 4–5
- personality
  - in Alzheimer's disease 53
  - and delirium 35
  - and depression 111–112
  - premorbid 6–7
  - traits 163
- personality disorder 163–168, 213
  - associated disorders 165–167
  - and dementia 166–167
  - and depression 165
  - management 167
  - in older people 165
  - outcome 167–168
  - patient management problem 335
  - prevalence 165
    - and schizophrenia 165–166
    - and somatisation disorder 166
- PET *see* positron emission tomography
- phantom boarder syndrome 52
- pharmacodynamics 248
- pharmacokinetics 247
- phenelzine 252
- phenobarbitol 259
- phenothiazines 257
- phenyldantoin 259
- phenytoin
  - in alcohol withdrawal regime 175
  - interactions with alcohol 172
- phobic disorder 136, 139–140, 271
- phosphodiesterases 187
- phosphomonoesters 187
- phosphorus spectroscopy 187
- physical examination 8–9
  - in Alzheimer's disease 57
  - in delirium 42
  - in depression 107
- physical health of residents in nursing/ residential homes 233
- physical illness
  - concurrent with dementia 88–90
  - concurrent with depression 104, 107, 111, 210–211, 320
  - effects on research studies 320
- physicians, role in residential care 239
- physiotherapy 239
- physostigmine 184
- Pick bodies 81
- Pick cells 81
- Pick's disease 55, 59, 65, 80–81
- pimozide 257, 259
- piracetam 249
- placebos 314–315
- plaques
  - in Alzheimer's disease 65–66
  - in late paraphrenia 156
- Police and Criminal Evidence Act 1984 298
- population projections 16, 17
- positron emission tomography (PET) 181, 248
  - advantages and disadvantages 181
  - dementia 58, 185–186
- post-traumatic stress disorder 274
- power of attorney 300
- praxis assessment 11
- prescribing in residential care 239
- presenilin genes 62
- Present Behavioural Examination 53
- presenting complaint 4
- prevalence, definition 18
- primary health care in management of dementia 97–98
- prion 82
- procyclidine 44
- progressive small vessel disease 74–75
- progressive supranuclear palsy 55, 65
- promazine 256, 259
- propranolol 259
- prosopagnosia 52
- proton spectroscopy 186–187
- pseudodelirium 40
- pseudodementia 105–106, 117, 188
- psychiatric history 5
- psychiatrist 199–200
  - relationship with geriatric physician 219–221
  - role in liaison service 219
- psychogeriatric services 193–208
  - development 193–198
  - links with other services 204–205, 206
  - patient management problem 336–337
  - range available 199–204
  - research on 323

- psychological therapies 115, 265–278, 322, 338–339
- psychomotor disturbance in delirium 31–32
- psychotherapy 115, 266–268, 322
- quality control, epidemiology 24
- radioligands 181
- randomised controlled trial 314
- rating instruments 9–14
  - Alzheimer's disease 57
  - delirium 41–42
  - in depression 12–13, 109
- rCBF *see* regional cerebral blood flow
- reality orientation 272–273
- regional cerebral blood flow (rCBF) 181
  - in dementia 184–185
- relatives, interviewing 3
- reminiscence 273–274
- renal failure and dementia 55
- repeatability of epidemiology studies 24
- research 19–20, 313–326
  - ethics 314–316, 317–318
  - future areas 324
  - patient management problem 341
  - principles 313–314
  - problems and challenges 319–324
  - stages 316–318
  - study types 314
- residential homes
  - accreditation 236
  - characteristics 235–242
  - and demography 225
  - distribution 235
  - historical context 226–231
  - life style and quality within 237–238
  - ownership 235
  - patient management problem 337–338
  - physical health care within 238–240
  - resident characteristics 232–235
  - size 235–236
  - staffing 236–237
- resolution therapy 275
- respiratory failure and delirium 36
- respite care 96, 237, 283–284, 323
- restraint 214
- reversible inhibitors of monoamine oxidase A enzyme (RIMA) agents 252, 253
- risk 21
- risperidone 257, 258
  - in delirium 44
  - in dementia 251
  - side-effects 259
- rivastigmine 248, 249
- safety of people with dementia 94–95
- sampling 22
- schizophrenia 149, 213
  - classification 151
  - diagnosis 152
  - differential diagnosis 40–41
  - drug therapy 257–260
  - family history 156
  - maintenance therapy 259–260
  - and personality disorder 165–166
  - risk factors 153
  - symptoms 150–151
  - treatment-resistant 259
- sedation
  - in delirium 44
  - rapid 261–262
- sedatives, pharmacodynamics 248
- selection bias 21
- selective serotonin reuptake inhibitors (SSRIs) 252, 256
  - drug interactions 254
  - side-effects 253
  - see also* antidepressants
- self-harm, deliberate 105, 210
- senium 1
- sensory deprivation and delirium 34
- serotonergic syndrome 254
- sertindole 257
- sertraline 252, 253
- sexual behaviour 168
- sexual disinhibition in dementia 92
- sheltered schemes 228
- Short-CARE 14
- sildenafil 168
- single photon emission computed tomography (SPECT) 181
  - Alzheimer's disease 58, 184
  - depression 189
- sleep disturbance and delirium 34–35
  - therapy 260–261

- sleep-wake cycle disorders in delirium 32
- smoking and Alzheimer's disease 63
- social admissions 203, 210
- social history 6
- social isolation and late paraphrenia 154
- social security benefits
  - appointeeship system 300
  - authorised agents 299
- social services
  - and demography 18
  - links with psychogeriatric services 204-205
- social support and depression 112, 113, 116
- somatisation disorder 136, 142, 166
- somatostatin in Alzheimer's disease 69
- SPECT *see* single photon emission
  - computed tomography
- speech assessment 7
- SSRIs *see* selective serotonin reuptake inhibitors
- staffing in residential care 236-237
- standardised rates, definition 18
- stress *see* carers, stress
- stroke, cognitive deficits following 73-74
- subcortical arteriosclerotic encephalopathy 74-75
- suicide
  - definition 22
  - and depression 118
- sulpiride 257, 258
  - in dementia 250
  - side-effects 259
- sundowning 91-92
- supervised discharge 308-309
- supervision 307-309
- support groups in depression 120
- surveys 19
  
- tacrine 184, 322
- tau 65
- temazepam
  - in delirium 44
  - in sleep disorders 260, 261
- temporal arteritis and delirium 36
- temporal lobe volume 183
- testamentary capacity 296
  
- thiamine
  - in alcohol withdrawal regime 175
  - in Alzheimer's disease 249
  - deficiency 84
- thioridazine 158, 257
  - in dementia 250
  - in mania 256
  - side-effects 259
- thioxanthenes 257
- third age 16-17
- thought content disorders in
  - Alzheimer's disease 52
- thyroid disease
  - and Alzheimer's disease 63
  - and dementia 55
- time, distorted perception in delirium 30
- tolbutamide 172
- total brain activity 181
- transference 266
- tranylcypromine 252
- trazodone 252
  - in dementia 251
  - side-effects 253
- tremor in delirium 32
- triclofos sodium 261
- trifluoperazine 158, 257, 259
  
- ubiquitin 65
- uncooperativeness in dementia 93
- urinary tract infection and delirium 36
- validation therapy 274
- validity of epidemiology studies 24
- valproate 130-131
- vascular dementia 55, 73-79
  - aetiology 73-75, 77-79
  - clinical features 75-76
  - diagnostic criteria 74
  - drug therapy 249-250
  - epidemiology 75
  - imaging 183, 185, 187
  - investigations 76-77
  - management 77
  - patient management problem 330-331
  - presentation 73
  - prognosis 77
  - types 79
- vasculitis, cerebral 78

- visual impairment and late paraphrenia 154
- vitamin deficiencies
  - in alcohol dependence 171
  - and dementia 55, 83–84
  - and depression 107
- vitamin supplementation in alcohol withdrawal regime 175
- voluntary services 205
- voting 294
- wandering 91
- ward consultations 216
- warfarin
  - interactions with alcohol 172
  - interactions with antidepressants 254
- Wernicke's encephalopathy 84, 172–173
- Whipple's disease 55, 83
- wills 296–297
- witness, serving as 298
- workhouse 226
- yaws 83
- zopiclone 261